|
1.
|
Barnholtz-Sloan JS, Schwartz AG, Qureshi
F, Jacques S, Malone J and Munkarah AR: Ovarian cancer: changes in
patterns at diagnosis and relative survival over the last three
decades. Am J Obstet Gynecol. 189:1120–1127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
3.
|
Liu CM: Cancer of the ovary. N Engl J Med.
352:1268–1269; author reply 1268–1269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kwon MJ and Shin YK: Epigenetic regulation
of cancer-associated genes in ovarian cancer. Int J Mol Sci.
12:983–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Li E, Bestor TH and Jaenisch R: Targeted
mutation of the DNA methyltransferase gene results in embryonic
lethality. Cell. 69:915–926. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Li E, Beard C and Jaenisch R: Role for DNA
methylation in genomic imprinting. Nature. 366:362–365. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Okano M, Bell DW, Haber DA and Li E: DNA
methyltransferases Dnmt3a and Dnmt3b are essential for de novo
methylation and mammalian development. Cell. 99:247–257. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Weber M, Hellmann I, Stadler MB, et al:
Distribution, silencing potential and evolutionary impact of
promoter DNA methylation in the human genome. Nat Genet.
39:457–466. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Gu W and Roeder RG: Activation of p53
sequence-specific DNA binding by acetylation of the p53 C-terminal
domain. Cell. 90:595–606. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Marzio G, Wagener C, Gutierrez MI,
Cartwright P, Helin K and Giacca M: E2F family members are
differentially regulated by reversible acetylation. J Biol Chem.
275:10887–10892. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ammanamanchi S, Freeman JW and Brattain
MG: Acetylated sp3 is a transcriptional activator. J Biol Chem.
278:35775–35780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
de Ruijter AJ, van Gennip AH, Caron HN,
Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs):
characterization of the classical HDAC family. Biochem J. 370(Pt
3): 737–749. 2003.PubMed/NCBI
|
|
14.
|
Gregoretti IV, Lee YM and Goodson HV:
Molecular evolution of the histone deacetylase family: functional
implications of phylogenetic analysis. J Mol Biol. 338:17–31. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Mizuno S, Chijiwa T, Okamura T, et al:
Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal
hematopoiesis and in acute and chronic myelogenous leukemia. Blood.
97:1172–1179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Yang B, Guo M, Herman JG and Clark DP:
Aberrant promoter methylation profiles of tumor suppressor genes in
hepatocellular carcinoma. Am J Pathol. 163:1101–1107. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Girault I, Tozlu S, Lidereau R and Bièche
I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in
sporadic breast carcinomas. Clin Cancer Res. 9:4415–4422.
2003.PubMed/NCBI
|
|
18.
|
Ahluwalia A, Hurteau JA, Bigsby RM and
Nephew KP: DNA methylation in ovarian cancer. II. Expression of DNA
methyltransferases in ovarian cancer cell lines and normal ovarian
epithelial cells. Gynecol Oncol. 82:299–304. 2001.PubMed/NCBI
|
|
19.
|
Omisanjo OA, Biermann K, Hartmann S, et
al: DNMT1 and HDAC1 gene expression in impaired spermatogenesis and
testicular cancer. Histochem Cell Biol. 127:175–181. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Weichert W: HDAC expression and clinical
prognosis in human malignancies. Cancer Lett. 280:168–176. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Weichert W, Röske A, Gekeler V, et al:
Histone deacetylases 1, 2 and 3 are highly expressed in prostate
cancer and HDAC2 expression is associated with shorter PSA relapse
time after radical prostatectomy. Br J Cancer. 98:604–610. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhou Q, Agoston AT, Atadja P, Nelson WG
and Davidson NE: Inhibition of histone deacetylases promotes
ubiquitin-dependent proteasomal degradation of DNA
methyltransferase 1 in human breast cancer cells. Mol Cancer Res.
6:873–883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
You JS, Kang JK, Lee EK, et al: Histone
deacetylase inhibitor apicidin downregulates DNA methyltransferase
1 expression and induces repressive histone modifications via
recruitment of corepressor complex to promoter region in human
cervix cancer cells. Oncogene. 27:1376–1386. 2008. View Article : Google Scholar
|
|
24.
|
Fuks F, Burgers WA, Brehm A, Hughes-Davies
L and Kouzarides T: DNA methyltransferase Dnmt1 associates with
histone deacetylase activity. Nat Genet. 24:88–91. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Boumber Y and Issa JP: Epigenetics in
cancer: what’s the future? Oncology (Williston Park). 25:220–226.
228:2011.
|
|
26.
|
Marks PA: Epigenetic targeted anti-cancer
drugs: an unfolding story. Oncology (Williston Park).
25:2312352011.PubMed/NCBI
|
|
27.
|
Benda JA and Zaino R: GOG Pathology
Manual. Buffalo, NY: Gynecologic Oncology Group; 1994
|
|
28.
|
Staging announcement: FIGO cancer
committee. Gynecol Oncol. 25:41986.
|
|
29.
|
Tsankova N, Renthal W, Kumar A and Nestler
EJ: Epigenetic regulation in psychiatric disorders. Nat Rev
Neurosci. 8:355–367. 2007. View
Article : Google Scholar
|
|
30.
|
Halusková J: Epigenetic studies in human
diseases. Folia Biol (Praha). 56:83–96. 2010.
|
|
31.
|
Mandrekar P: Epigenetic regulation in
alcoholic liver disease. World J Gastroenterol. 17:2456–2464. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Brait M and Sidransky D: Cancer
epigenetics: above and beyond. Toxicol Mech Methods. 21:275–288.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ferguson LR, Tatham AL, Lin Z and Denny
WA: Epigenetic regulation of gene expression as an anticancer drug
target. Curr Cancer Drug Targets. 11:199–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Maldonado L and Hoque MO: Epigenomics and
ovarian carcinoma. Biomark Med. 4:543–570. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Abbas A and Gupta S: The role of histone
deacetylases in prostate cancer. Epigenetics. 3:300–309. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Weichert W, Denkert C, Noske A, et al:
Expression of class I histone deacetylases indicates poor prognosis
in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasia. 10:1021–1027. 2008.PubMed/NCBI
|
|
38.
|
Hayashi A, Horiuchi A, Kikuchi N, et al:
Type-specific roles of histone deacetylase (HDAC) overexpression in
ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3
stimulates cell migration with downregulation of E-cadherin. Int J
Cancer. 127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Song J, Noh JH, Lee JH, et al: Increased
expression of histone deacetylase 2 is found in human gastric
cancer. APMIS. 113:264–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Sun L, Hui AM, Kanai Y, Sakamoto M and
Hirohashi S: Increased DNA methyltransferase expression is
associated with an early stage of human hepatocarcinogenesis. Jpn J
Cancer Res. 88:1165–1170. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Braconi C, Huang N and Patel T:
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor
suppressor gene expression by interleukin-6 in human malignant
cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
|
|
42.
|
Wang L, Zou X, Berger AD, et al: Increased
expression of histone deacetylaces (HDACs) and inhibition of
prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J
Transl Res. 1:62–71. 2009.PubMed/NCBI
|
|
43.
|
Tariq M, Saze H, Probst AV, Lichota J,
Habu Y and Paszkowski J: Erasure of CpG methylation in Arabidopsis
alters patterns of histone H3 methylation in heterochromatin. Proc
Natl Acad Sci USA. 100:8823–8827. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP
and Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA
methylation to histone methylation. J Biol Chem. 278:4035–4040.
2003. View Article : Google Scholar : PubMed/NCBI
|
